Henry Schein (Nasdaq: HSIC ) is expected to report Q2 earnings on Aug. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Henry Schein's revenues will increase 8.7% and EPS will increase 11.7%.
The average estimate for revenue is $2.39 billion. On the bottom line, the average EPS estimate is $1.24.
Last quarter, Henry Schein chalked up revenue of $2.29 billion. GAAP reported sales were 9.3% higher than the prior-year quarter's $2.10 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $1.06. GAAP EPS of $1.03 for Q1 were 16% higher than the prior-year quarter's $0.89 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 28.2%, 90 basis points worse than the prior-year quarter. Operating margin was 6.7%, 20 basis points worse than the prior-year quarter. Net margin was 4.0%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $9.60 billion. The average EPS estimate is $4.89.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 99 members out of 112 rating the stock outperform, and 13 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Henry Schein a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Henry Schein is hold, with an average price target of $88.46.
Is Henry Schein the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Henry Schein to My Watchlist.